Comparative effectiveness research on the treatment outcomes of subcutaneous (SC) and intravenous (IV) bortezomib (BTZ) in newly diagnosed multiple myeloma (NDMM) patients (PTS)

Category Primary study
JournalBlood
Year 2015
This article has no abstract
Epistemonikos ID: f7f31a2d2b74a69d2d40f1ddaaa40011596f087c
First added on: Feb 07, 2025